Scientific and legal viability of follow-on protein drugs.
Dudzinski
David M
DM
Department of Medicine, Massachusetts General Hospital, Boston, USA.
Kesselheim
Aaron S
AS
D001688:Biological Products / Q000592:standards; D017277:Drug Approval / Q000266:history / Q000331:legislation & jurisprudence*; D016568:Drugs, Generic / Q000266:history / Q000592:standards; D033161:Government Regulation; D049673:History, 20th Century; D006801:Humans; D007880:Legislation, Drug / Q000266:history; D010330:Patents as Topic / Q000331:legislation & jurisprudence; D011994:Recombinant Proteins / Q000592:standards; D014481:United States; D014486:United States Food and Drug Administration
D001688:Biological Products; D016568:Drugs, Generic; D011994:Recombinant Proteins